缬沙坦对肝硬化患者血清血管紧张素ⅡTGF-β1的影响

The Influence of Valsartan on Liver Cirrhosis in Serum Angiotension Ⅱ(AngⅡ) and Transforming Growth Factor-beta 1(TGF-β1)

目的:探讨缬沙坦对肝硬化患者血清血管紧张素Ⅱ(AngⅡ)转化生长因子-β1(TGF-β1)的影响及意义。方法:40例肝硬化患者被随机分为治疗组和对照组各20例,两组均给予常规治疗,治疗组在常规治疗基础上加用缬沙坦80mg/d,于治疗前及治疗6个月时采用ELISA法检测血清AngⅡ、TGF-β1。结果:治疗前肝硬化患者血清AngⅡ(167.84±64.81vs 51.13±15.95pg/l)及TGFβ1(181.12±32.63 vs31.46±10.39μg/l)水平均明显高于健康人,应用缬沙坦治疗后血清AngⅡ(168.67±69.03vs218.46±74.79 pg/l)较治疗前升高,而血清TGFβ1(182.22±30.60vs121.77±13.84μg/l)较治疗前下降,差异均有显著性。结论:血管紧张素ⅡⅠ型受体拮抗剂缬沙坦能降低血清TGFβ1水平,具有一定的抗纤维化作用。

Objective： To investigate the influence and clinical effect of valsartan on liver cirrhosis in serum Ang Ⅱ and TGF- β1. Method： 40 liver cirrhsis patients were randomly divided into two groups ： treatment group and control group,20 cases in each group. The control group was treated with routine treatment,the treatment group,besides routine with treatment ,was added valsartan 80mg/day . Before treatment and after 6 months ELISA techniques were used to detect the levels of serum Ang Ⅱ and TGFβ1 in 40 patients with liver cirrhosis . Result： Before treatment the levels of serum Ang Ⅱ （ 167.84 ±64.81vs 51.13 ± 15.95pg/1） and TGF - β1 （ 181.12 ± 32.63 vs31.46 ±10.39μg/1） in liver cirrhosis were significantly higher than that in health peason, After treated with valsartan , serum Ang Ⅱ （ 168.67 ± 69.03vs218.46 ± 74.79 pg/1） in after treatment 6 months was significantly higher than that before treatment , but TGF - β1 （ 182.22 ±30.60vs121.77 ± 13.84μg/1） was lower significantly than that before. Conclusion： Angiotensin Ⅱ type Ⅰ receptor blocker valsartan can reduce the levels of serum TGFβ1, it can retard the progression of hepatic fibrosis.